Merck KGaA Forms Global Fertility Alliance
Merck KGaA has formed the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. The alliance is a partnership between the biopharmaceutical business of Merck KGaA, Illumina, a company developing and commercializing systems for analysis of genetic variation and function, and Genea Limited, Sydney, Australia, which develops fertility technologies.
With the establishment of the alliance, the biopharmaceuticals business of Merck, KGaA, Illumina and Genea seek to advance progress and innovation in ART in three ways: foster integration of multiple, leading fertility technologies; collaborate with healthcare professionals and medical societies to develop global standards; and develop educational resources for healthccare professionals worldwide. These efforts will include training curricula and workshops as well as access to model labs, symposia, and events at medical meetings.
Source: Merck KGaA